denosumab (Xgeva) Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.
denosumab (Xgeva) prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone.
denosumab (Prolia) Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
denosumab (Prolia) Bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
denosumab (Xgeva) Adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity
